A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 15 Oct 2014
At a glance
- Drugs Everolimus (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2011 New trial record